戴维医疗(300314) - 2024 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2024 was CNY 155,328,964.53, a decrease of 1.94% compared to CNY 157,862,759.12 in the same period last year[21] - The company's net profit for Q1 2024 was CNY 38,107,228.76, down from CNY 50,019,287.49 in the same period last year, representing a decrease of approximately 23.9%[49] - Operating profit for the first quarter was CNY 44,488,936.73, compared to CNY 57,880,407.58 in Q1 2023, reflecting a decline of about 23.0%[49] - Net profit attributable to shareholders of the listed company is ¥38,107,228.76, down 23.81% from ¥50,019,287.49 in the previous year[29] - The company reported a total comprehensive income of ¥38,107,228.76 for the current period, compared to ¥50,019,287.49 in the previous year[24] Cash Flow and Assets - The net cash flow from operating activities is -¥10,331,039.53, a decline of 249.65% compared to ¥6,903,274.52 in the same period last year[29] - Cash and cash equivalents at the end of the period are ¥443,087,497.54, down from ¥409,457,239.69 at the end of the previous year[25] - The company's cash and cash equivalents decreased from CNY 571,365,961.98 to CNY 456,258,061.24, a decline of approximately 20.1%[39] - Total assets at the end of the reporting period amount to ¥1,364,964,670.42, a decrease of 0.66% from ¥1,374,082,918.93 at the end of the previous year[29] - The total assets of Ningbo David Medical Instruments Co., Ltd. amounted to CNY 1,364,964,670.42, a slight decrease from CNY 1,374,082,918.93[39] Liabilities and Equity - The total liabilities decreased from CNY 210,610,507.00 at the beginning of the period to CNY 163,520,520.34 at the end of the period, reflecting a reduction of approximately 22.34%[21] - The total equity attributable to shareholders increased from CNY 1,163,472,411.93 to CNY 1,201,444,150.08, representing a growth of about 3.26%[21] - Shareholders' equity attributable to the listed company is ¥1,201,444,150.08, an increase of 3.26% from ¥1,163,472,411.93[29] - The accounts payable decreased from CNY 119,209,647.28 to CNY 99,484,516.41, a reduction of approximately 16.6%[39] Expenses and Investments - Research and development expenses increased to CNY 10,287,345.11 from CNY 8,627,320.97, marking a rise of approximately 19.2%[49] - The total operating costs for the quarter were CNY 108,971,100.08, slightly down from CNY 110,973,756.29, indicating a decrease of about 1.8%[49] - Financial expenses increased by 1072.24% to -¥2,740,443.68 due to reduced exchange loss from currency fluctuations[32] - Investment income decreased by 138.73% to -¥2,554,623.67 mainly due to reduced investment income accounted for using the equity method[32] Receivables and Prepayments - Accounts receivable increased by 99.35% to ¥47,493,541.24 due to increased credit limits granted to distributors[32] - Prepayments rose by 92.35% to ¥26,205,071.44 primarily due to increased prepayments for raw materials and outsourced R&D[32] - The accounts receivable increased significantly to CNY 47,493,541.24 from CNY 23,824,645.62, representing an increase of about 99.5%[39] Government Support and Transparency - The company received government subsidies amounting to CNY 1,084,655.18 during the quarter, contributing positively to the financial results[10] - The company maintains a commitment to transparency, ensuring that all financial disclosures are accurate and complete[6] - The company has not classified any non-recurring gains or losses as regular operating income, ensuring clarity in financial reporting[12]